Pharmaguy's Insights Into Drug Industry News
186.0K views | +0 today
Follow
Pharmaguy's Insights Into Drug Industry News
Pharmaguy curates and provides insights into selected drug industry news and issues.
Curated by Pharma Guy
Your new post is loading...
Your new post is loading...
Scooped by Pharma Guy
Scoop.it!

Why Google and Novartis are teaming up

Why Google and Novartis are teaming up | Pharmaguy's Insights Into Drug Industry News | Scoop.it
First there was Google Glass. Now, there might be Google contact lenses.


They're working on smart lenses that will be able to monitor blood sugar levels for diabetics through the natural tears in our eyes.  


Google and Novartis also say they’re developing another lens that can auto-focus the eye. It could help with reading, because as the eye ages, it’s harder to see things up close.   


The two companies complement each other pretty well: Google doesn’t need any money from Novartis, while Novartis can help Google navigate the clinical and regulatory side of things.


“They need more the expertise in terms of running clinical trials, getting approval from the FDA, and then marketing after approval,” says John Mack, who follows the pharmaceutical industry as publisher of "Pharma Marketing News."

Pharma Guy's insight:


Just to clarify: Yes, FDA went after pharma companies because of paid Google ads that did not contain relevant risk info and yes, Google encouraged these kinds of ads (google "Girl from Google" to learn more about that). But, as I mentioned to Nancy on the phone (but not quoted here), the real reason Google DEFINITELY can use an FDA go-between is because it was caught in an FDA sting operation soliciting ads from illegal online pharmacies despite its own policy not to accept such ads. FDA posed as an illegal pharmacy in the sting operation. For more on that, read "How FDA, in Cahoots with DOJ, Brought Google Down

more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

Novartis buys rights to Google's 'smart lens' technology

Novartis buys rights to Google's 'smart lens' technology | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Novartis has licensed Google's new 'smart lens' technology in a deal that will see its eye health unit Alcon work with the technology company develop new types of contact lenses. 


The technology combines non-invasive sensors, microchips and other miniaturised electronics which are so small they resemble bits of glitter embedded within contact lenses.  


Google revealed earlier this year it was testing smart contact lens that can measure diabetes patients' glucose levels via their tears and connect wirelessly with a mobile device to store this information.  


Applying the minimally invasive technology within the diabetes arena to reduce the burden of regular blood glucose tests is one of the key areas of interest for Novartis in its new deal with Google.  


The other is to help people with presbyopia – age-related long-sightedness that makes it more difficult to focus on objects that are near.  

Novartis hopes people with presbyopia who can no longer read without glasses could benefit from a smart lens, either in the form of an accommodative contact lens or an intraocular lens, to help restore the eye's natural autofocus as part of refractive cataract treatment.  

Pharma Guy's insight:


The agreement, which remains subject to anti-trust approvals, would also allow Google to avoid having to deal with some of the "painful regulation" issues imposed by FDA.


Read: "Heavy regulation makes healthcare a painful business," Says Google's Brin

more...
No comment yet.